Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: FASEB J. 2021 Apr;35(4):e21437. doi: 10.1096/fj.202002755R

Figure 3. CaMKIIδ is upregulated in a JAK-dependent manner.

Figure 3.

A. qPCR analysis of CaMKIIδ expression after 3h IL-6/sIL-6r treatment following a 30-minute treatment with 2 μM ruxolitinib. n = 4, Two-way ANOVA, p < 0.05 B. Immunoblot of confluent HUVEC treated with or without 2 μM ruxolitinib and 3, 24h IL-6/sIL-6r treatment. Normalization of pan-CaMKII expression relative to the β-actin expression is shown. n = 3, Two-way ANOVA, (*) p < 0.05.